Copaxone, still growing, helps Teva pass Q3 estimates

Sales of Teva's ($TEVA) multiple sclerosis drug, Copaxone, are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales. That, in turn, helped profit hit $1.32 per share, passing analysts' estimates. And speaking of that Supreme Court appeal, CEO Erez Vigodman said Thursday that he's optimistic the court will rule in Teva's favor. Report | More

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…